Cargando…
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
Tyrosine kinase inhibitors (TKIs) such as imatinib improve the prognosis of patients with gastrointestinal stromal tumors (GISTs). However, treatment options for GISTs are still limited, and the continuation of TKIs is difficult due to adverse events in some cases. The effectiveness of low-dose imat...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938401/ https://www.ncbi.nlm.nih.gov/pubmed/36820072 http://dx.doi.org/10.1159/000529002 |
_version_ | 1784890621315514368 |
---|---|
author | Katsumata, Ryo Monobe, Yasumasa Katata, Yosuke Fujiwara, Hideyo Urano, Takashi Akagi, Akihisa Tsujimoto, Kotone Konishi, Takako Manabe, Noriaki Kamada, Tomoari Kawamoto, Hirofumi Yamatsuji, Tomoki Naomoto, Yoshio |
author_facet | Katsumata, Ryo Monobe, Yasumasa Katata, Yosuke Fujiwara, Hideyo Urano, Takashi Akagi, Akihisa Tsujimoto, Kotone Konishi, Takako Manabe, Noriaki Kamada, Tomoari Kawamoto, Hirofumi Yamatsuji, Tomoki Naomoto, Yoshio |
author_sort | Katsumata, Ryo |
collection | PubMed |
description | Tyrosine kinase inhibitors (TKIs) such as imatinib improve the prognosis of patients with gastrointestinal stromal tumors (GISTs). However, treatment options for GISTs are still limited, and the continuation of TKIs is difficult due to adverse events in some cases. The effectiveness of low-dose imatinib is unclear. We report 2 cases to show effectiveness of low-dose imatinib in patients with adverse events. The first case is a male in his early 60s with a history of intestinal GIST resection who was diagnosed with recurrent GIST with peritoneal dissemination. He was started on low-dose imatinib (300 mg) because of a history of subconjunctival hemorrhage after receiving postoperative imatinib. Follow-up contrast-enhanced ultrasonography revealed that the tumors had shrunk in size and number after 2 months of treatment with 300-mg imatinib. He continued this treatment and showed partial response for 8 months. The second case is a female in her late 70s with rectal GIST who was treated with imatinib 400 mg. Due to a severe skin lesion, she changed her treatment to sunitinib 2 months after initiation. However, new metastasis in the liver was confirmed after 4 months of administration of sunitinib. She underwent surgical esection of the rectal tumor to reduce the volume. After the surgery, low-dose imatinib (300 mg) with oral steroids was adopted. Follow-up confirmed the absence of recurrence at the rectum and no increase in hepatic tumor size for 18 months. Aggressive treatment with low-dose imatinib instead of discontinuation or alteration of treatment may benefit patients with unresectable and postoperative GISTs with sensible mutation to imatinib. |
format | Online Article Text |
id | pubmed-9938401 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-99384012023-02-19 Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib Katsumata, Ryo Monobe, Yasumasa Katata, Yosuke Fujiwara, Hideyo Urano, Takashi Akagi, Akihisa Tsujimoto, Kotone Konishi, Takako Manabe, Noriaki Kamada, Tomoari Kawamoto, Hirofumi Yamatsuji, Tomoki Naomoto, Yoshio Case Rep Gastroenterol Case Report Tyrosine kinase inhibitors (TKIs) such as imatinib improve the prognosis of patients with gastrointestinal stromal tumors (GISTs). However, treatment options for GISTs are still limited, and the continuation of TKIs is difficult due to adverse events in some cases. The effectiveness of low-dose imatinib is unclear. We report 2 cases to show effectiveness of low-dose imatinib in patients with adverse events. The first case is a male in his early 60s with a history of intestinal GIST resection who was diagnosed with recurrent GIST with peritoneal dissemination. He was started on low-dose imatinib (300 mg) because of a history of subconjunctival hemorrhage after receiving postoperative imatinib. Follow-up contrast-enhanced ultrasonography revealed that the tumors had shrunk in size and number after 2 months of treatment with 300-mg imatinib. He continued this treatment and showed partial response for 8 months. The second case is a female in her late 70s with rectal GIST who was treated with imatinib 400 mg. Due to a severe skin lesion, she changed her treatment to sunitinib 2 months after initiation. However, new metastasis in the liver was confirmed after 4 months of administration of sunitinib. She underwent surgical esection of the rectal tumor to reduce the volume. After the surgery, low-dose imatinib (300 mg) with oral steroids was adopted. Follow-up confirmed the absence of recurrence at the rectum and no increase in hepatic tumor size for 18 months. Aggressive treatment with low-dose imatinib instead of discontinuation or alteration of treatment may benefit patients with unresectable and postoperative GISTs with sensible mutation to imatinib. S. Karger AG 2023-02-17 /pmc/articles/PMC9938401/ /pubmed/36820072 http://dx.doi.org/10.1159/000529002 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Report Katsumata, Ryo Monobe, Yasumasa Katata, Yosuke Fujiwara, Hideyo Urano, Takashi Akagi, Akihisa Tsujimoto, Kotone Konishi, Takako Manabe, Noriaki Kamada, Tomoari Kawamoto, Hirofumi Yamatsuji, Tomoki Naomoto, Yoshio Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib |
title | Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib |
title_full | Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib |
title_fullStr | Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib |
title_full_unstemmed | Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib |
title_short | Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib |
title_sort | benefit of continuation of low-dose imatinib for gastrointestinal stromal tumors despite adverse events with regular-dose imatinib |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938401/ https://www.ncbi.nlm.nih.gov/pubmed/36820072 http://dx.doi.org/10.1159/000529002 |
work_keys_str_mv | AT katsumataryo benefitofcontinuationoflowdoseimatinibforgastrointestinalstromaltumorsdespiteadverseeventswithregulardoseimatinib AT monobeyasumasa benefitofcontinuationoflowdoseimatinibforgastrointestinalstromaltumorsdespiteadverseeventswithregulardoseimatinib AT katatayosuke benefitofcontinuationoflowdoseimatinibforgastrointestinalstromaltumorsdespiteadverseeventswithregulardoseimatinib AT fujiwarahideyo benefitofcontinuationoflowdoseimatinibforgastrointestinalstromaltumorsdespiteadverseeventswithregulardoseimatinib AT uranotakashi benefitofcontinuationoflowdoseimatinibforgastrointestinalstromaltumorsdespiteadverseeventswithregulardoseimatinib AT akagiakihisa benefitofcontinuationoflowdoseimatinibforgastrointestinalstromaltumorsdespiteadverseeventswithregulardoseimatinib AT tsujimotokotone benefitofcontinuationoflowdoseimatinibforgastrointestinalstromaltumorsdespiteadverseeventswithregulardoseimatinib AT konishitakako benefitofcontinuationoflowdoseimatinibforgastrointestinalstromaltumorsdespiteadverseeventswithregulardoseimatinib AT manabenoriaki benefitofcontinuationoflowdoseimatinibforgastrointestinalstromaltumorsdespiteadverseeventswithregulardoseimatinib AT kamadatomoari benefitofcontinuationoflowdoseimatinibforgastrointestinalstromaltumorsdespiteadverseeventswithregulardoseimatinib AT kawamotohirofumi benefitofcontinuationoflowdoseimatinibforgastrointestinalstromaltumorsdespiteadverseeventswithregulardoseimatinib AT yamatsujitomoki benefitofcontinuationoflowdoseimatinibforgastrointestinalstromaltumorsdespiteadverseeventswithregulardoseimatinib AT naomotoyoshio benefitofcontinuationoflowdoseimatinibforgastrointestinalstromaltumorsdespiteadverseeventswithregulardoseimatinib |